Bart Neyns
Impact in
- Oncology top 0.05%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Colorectal Cancer Treatments and Studies
- Cutaneous Melanoma Detection and Management
- Immunology top 0.1%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
Papers in
- Co-authors
- Sofie Wilgenhof (32 shared papers)Kris Thielemans (28 shared papers)Eric Van Cutsem (7 shared papers)Alain Hendlisz (6 shared papers)Carlo Heirman (20 shared papers)Jurgen Corthals (20 shared papers)Jean‐Jacques Grob (6 shared papers)Salvatore Siena (3 shared papers)
- Journals
- Annals of Oncology (41 papers)European Journal of Cancer (22 papers)Melanoma Research (20 papers)Journal for ImmunoTherapy of Cancer (12 papers)Cancers (11 papers)
- Partner nations
- BelgiumUnited StatesNetherlands
In The Last Decade
Bart Neyns
271 papers receiving 24.7k citations
Bart Neyns's Hit Papers
Peers
Comparison fields: 5 of 143
- Oncology 15.5k
- Immunology 7.4k
- Genetics 2.4k
- Cancer Research 1.9k
- Pulmonary and Respiratory Medicine 3.1k
Countries citing papers authored by Bart Neyns
This map shows the geographic impact of Bart Neyns's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bart Neyns with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bart Neyns more than expected).
Fields of papers citing papers by Bart Neyns
This network shows the impact of papers produced by Bart Neyns. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bart Neyns. The network helps show where Bart Neyns may publish in the future.
Co-authors
The 25 scholars most cited alongside Bart Neyns, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 284 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pembrolizumab versus Ipilimumab in Advanced Melanoma Hit paper breakdown → | 2015 | 4893 |
| 2 | Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial Hit paper breakdown → | 2015 | 2293 |
| 3 | Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer Hit paper breakdown → | 2018 | 1672 |
| 4 | Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Hit paper breakdown → | 2007 | 1653 |
| 5 | Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study Hit paper breakdown → | 2009 | 1033 |
| 6 | Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) Hit paper breakdown → | 2017 | 1007 |
| 7 | Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study Hit paper breakdown → | 2019 | 937 |
| 8 | Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization Hit paper breakdown → | 2021 | 512 |
| 9 | Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis Hit paper breakdown → | 2017 | 496 |
| 10 | Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma Hit paper breakdown → | 2013 | 482 |
| 11 | Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial Hit paper breakdown → | 2017 | 442 |
| 12 | 2010 | 370 | |
| 13 | 2016 | 268 | |
| 14 | 2014 | 234 | |
| 15 | 2020 | 216 | |
| 16 | Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142 Hit paper breakdown → | 2022 | 206 |
| 17 | 2019 | 205 | |
| 18 | 2009 | 204 | |
| 19 | 2016 | 189 | |
| 20 | 2019 | 185 |
About Bart Neyns
Bart Neyns is a scholar working on Oncology, Genetics, Immunology, Pulmonary and Respiratory Medicine and Molecular Biology, having authored 284 papers that have together received 25.3k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (78 papers), Immunotherapy and Immune Responses (53 papers), Glioma Diagnosis and Treatment (47 papers), Melanoma and MAPK Pathways (47 papers), CAR-T cell therapy research (46 papers), Cutaneous Melanoma Detection and Management (36 papers), Brain Metastases and Treatment (31 papers) and Colorectal Cancer Treatments and Studies (17 papers). The work is most often cited by research in Oncology (15.5k citations), Immunology (7.4k citations), Genetics (2.4k citations), Cancer Research (1.9k citations) and Pulmonary and Respiratory Medicine (3.1k citations). Bart Neyns has collaborated with scholars based in Belgium, United States and Netherlands. Frequent co-authors include Sofie Wilgenhof, Kris Thielemans, Eric Van Cutsem, Alain Hendlisz, Carlo Heirman, Jurgen Corthals, Jean‐Jacques Grob, Salvatore Siena, Marc Peeters and Yves Humblet. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, Melanoma Research, Journal for ImmunoTherapy of Cancer and Cancers.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.